CGIM
TBPH icon

Cannon Global Investment Management’s Theravance Biopharma TBPH Stock Holding History

Cannon Global Investment Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Sell
10,321
-5,726
-36% -$94.8K 0.5% 50
2026
Q1 		$260K Buy
+16,047
New +$284K 0.51% 60
2022
Q4 		– Sell
-65,000
Closed -$659K – 31
2022
Q3 		$659K Buy
+65,000
New +$609K 1.06% 22

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cannon Global Investment Management's TBPH Position: Q2 2026 in Review

Cannon Global Investment Management reduced its Theravance Biopharma (TBPH) stake by 36% in Q2 2026, selling an estimated $94.8K and leaving 10,321 shares worth $175K. The position accounts for 0.5% of the portfolio, ranked #50.

Cannon Global Investment Management first reported a position in TBPH in Q3 2022 and has held it in 3 quarters since. The position peaked at $659K in Q3 2022. 179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Cannon Global Investment Management held 10,321 shares of Theravance Biopharma worth $175K as of Q2 2026.
  • Cannon Global Investment Management sold 5,726 Theravance Biopharma shares in Q2 2026, an estimated $94.8K.
  • Theravance Biopharma made up 0.5% of Cannon Global Investment Management's portfolio in Q2 2026, its #50 holding.
  • Cannon Global Investment Management first reported a position in Theravance Biopharma in Q3 2022 and has held it in 3 quarters since.
  • Cannon Global Investment Management's Theravance Biopharma position peaked at $659K in Q3 2022.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Cannon Global Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.